INCB 057643

Drug Profile

INCB 057643

Alternative Names: INCB 57643; INCB057643

Latest Information Update: 23 Jun 2016

Price : $50

At a glance

  • Originator Incyte Corporation
  • Class Antineoplastics
  • Mechanism of Action Bromodomain and extraterminal domain protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Cancer

Most Recent Events

  • 23 Jun 2016 Phase-I/II clinical trials in Cancer in USA (unspecified route)
  • 01 May 2016 Incyte Corporation initiates enrolment in a Phase II/II trial for Advanced Cancer (Late-stage disease, Second-line therapy or greater) in USA (NCT02711137)
  • 12 Mar 2016 Incyte Corporation plans a phase I/II trial for Cancer (Late-stage disease, Second-line therapy or greater) in USA (NCT02711137)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top